These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25426665)

  • 1. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.
    Tong X; Li J; Zhou Z; Zheng D; Liu J; Su C
    Leuk Lymphoma; 2015 Jun; 56(6):1911-3. PubMed ID: 25426665
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of single-agent decitabine in atypical chronic myeloid leukemia.
    Hausmann H; Bhatt VR; Yuan J; Maness LJ; Ganti AK
    J Oncol Pharm Pract; 2016 Dec; 22(6):790-794. PubMed ID: 26378157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine studies in chronic and acute myelogenous leukemia.
    Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
    Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
    [No Abstract]   [Full Text] [Related]  

  • 4. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
    Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
    Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
    Kantarjian HM; O'Brien SM; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios MB; de Vos D; Talpaz M
    Leukemia; 1997 Oct; 11(10):1617-20. PubMed ID: 9324279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
    Iastrebner M; Jang JH; Nucifora E; Kim K; Sackmann F; Kim DH; Orlando S; Jung CW; Basquiera A; Klein G; Santini F; Bernard HI; Korin J; Taborda G
    Leuk Lymphoma; 2010 Dec; 51(12):2250-7. PubMed ID: 20929328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
    Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
    Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
    Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
    Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
    Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L
    Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722
    [No Abstract]   [Full Text] [Related]  

  • 13. A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.
    Shah D; Kumar R; Gaikazian S
    Haemophilia; 2014 Jan; 20(1):e92-4. PubMed ID: 24261579
    [No Abstract]   [Full Text] [Related]  

  • 14. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
    Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
    Liu Y; Tabarroki A; Billings S; Visconte V; Rogers HJ; Hasrouni E; Englehaupt R; Kalaycio M; Sekeres MA; Saunthararajah Y; Tiu RV
    Leuk Lymphoma; 2014 Feb; 55(2):447-9. PubMed ID: 23647061
    [No Abstract]   [Full Text] [Related]  

  • 16. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
    Wakim JJ; Tirado CA; Dowell J; Chen W
    Cancer Genet; 2012 Mar; 205(3):124-7. PubMed ID: 22469511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
    Quintás-Cardama A; Kantarjian H; Abruzzo LV; Cortes J
    Leukemia; 2007 Nov; 21(11):2394-6. PubMed ID: 17690707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.